脏炎症:机制,病理生理学和治疗前景
Jing Yan1, Fuying Zhao1, Ruitong Zhang2
1Department of Biochemistry & Molecular Biology, China Medical University, Shenyang 110122, China.
Ageing research reviews
|March 12, 2026
概括
慢性病 (CKD) 与加速衰老和炎症有关. 本综述强调了在衰老中的作用,探索了改善健康的机制和潜在疗法.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 老年学是一门学科.
- 免疫学 免疫学 免疫学
背景情况:
- 全球人口老龄化面临着慢性病 (CKD) 患病率的增加.
- 慢性病现在被视为由慢性炎症 (炎症) 驱动的加速衰老.
- 脏积极参与系统性炎症,受到免疫和代谢变化的影响.
研究的目的:
- 综合脏在全身炎症中的作用的证据.
- 探索驱动炎和相关病理的机制.
- 评估炎的诊断工具和治疗策略.
主要方法:
- 关于脏衰老和炎症的当前科学文献的综述.
- 分析脏炎症的细胞和分子机制.
- 对诊断生物标志物和治疗干预措施的评估.
主要成果:
- 居民细胞通过老化相关分泌表型 (SASP) 促进炎症.
- 关键机制包括NLRP3炎症酶,线粒体功能障碍,表观遗传学和肠-轴.
- 新兴的诊断 (衰老钟,生物标志物) 和治疗 (老化剂,SGLT2抑制剂) 是有前途的.
结论:
- 脏是衰老和炎症的积极参与者.
- 针对脏炎症具有改善健康状况的潜力.
- 未来的研究应该专注于分子地图,生物标志物试验和组合疗法.
相关概念视频
Inflammation
63.6K
Overview
63.6K
Inflammatory Response
18.0K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
18.0K
Inflammatory Response I: Vascular and Cellular
17.9K
The inflammatory response is the body's defense against infection, injury, or irritation from bacteria, trauma, toxins, or heat. Inflammation helps locate and destroy pathogens and remove damaged tissue elements to heal the body. During this initial phase, fluid, blood products, and nutrients migrate to the injured area, resulting in redness, heat, swelling, ache, and loss of function. Moreover, signs of systemic inflammation include fever, increased WBC count, malaise, anorexia, nausea,...
17.9K
Gastritis-II: Pathophysiology
1.7K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.7K
Inflammatory Bowel Disease IV: Pharmacological Management
893
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
893
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
579
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
579


